Found 12 hits in this display Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Platelet-derived growth factor receptor beta
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 19.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against PDGFRβ (PDGFRβ Kinase Enzyme System: Promega), were evaluated by mixing the... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |
Platelet-derived growth factor receptor beta
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 19.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Platelet-derived growth factor receptor alpha
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB
KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 24.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Platelet-derived growth factor receptor alpha
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB
KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 24.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against PDGFRα (PDGFRα Kinase Enzyme System: Promega), were evaluated by mixing the... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |
Fibroblast growth factor receptor 3
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 30 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against FGFR3 (FGFR3 Kinase Enzyme System: Promega), were evaluated by mixing the FGFR3 prote... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |
Fibroblast growth factor receptor 3
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 30 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT and 2 mM MnCl2. The inhibitory activities of compoun... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Fibroblast growth factor receptor 1
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 48.5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against FGFR1 (FGFR1 Kinase Enzyme System: Promega), were evaluated by mixing the FGFR1 prote... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |
Fibroblast growth factor receptor 1
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 48.5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Vascular endothelial growth factor receptor 2
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 83.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Vascular endothelial growth factor receptor 2
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 83.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against VEGFR2 (VEGFR2 Kinase Enzyme System: Promega), were evaluated by mixing the VEGFR2 pr... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |
Vascular endothelial growth factor receptor 1
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 178 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT and 2 mM MnCl2. The inhibitory activities of compoun... |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2XP784N |
More data for this Ligand-Target Pair | |
Vascular endothelial growth factor receptor 1
(Homo sapiens (Human)) | BDBM445229
(US10669235, Example 20 | US11208381, Example 20)Show SMILES COCCN1CCC(CC1)NC(=O)c1ccc(N\C(=C2/C(=O)Nc3cc(C(=O)OC)c(C)cc23)c2ccccc2)cc1 Show InChI InChI=1S/C33H36N4O5/c1-21-19-27-28(20-26(21)33(40)42-3)36-32(39)29(27)30(22-7-5-4-6-8-22)34-24-11-9-23(10-12-24)31(38)35-25-13-15-37(16-14-25)17-18-41-2/h4-12,19-20,25,34H,13-18H2,1-3H3,(H,35,38)(H,36,39)/b30-29- | PDB MMDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 178 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED
US Patent
| Assay Description The inhibitory activities of compounds of the invention against VEGFR1 (VEGFR1 Kinase Enzyme System: Promega), were evaluated by mixing the VEGFR1 pr... |
US Patent US10669235 (2020)
BindingDB Entry DOI: 10.7270/Q2XW4NVJ |
More data for this Ligand-Target Pair | |